-

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET.

The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Contacts

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Ryan Wong, 617-800-4112
rwong@sarepta.com

Tam Thornton, 617-803-3825
tthornton@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Release Versions

Contacts

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Ryan Wong, 617-800-4112
rwong@sarepta.com

Tam Thornton, 617-803-3825
tthornton@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

More News From Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan. Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta’...

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas. Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvov...

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its ninth year, the program was created to recognize individuals living with Duchenne muscular dystrop...
Back to Newsroom